[HTML][HTML] Clinical severity of SARS-CoV-2 omicron variant compared with delta among hospitalized COVID-19 patients in Belgium during autumn and winter season …
This retrospective multi-center matched cohort study assessed the risk for severe COVID-19
(combination of severity indicators), intensive care unit (ICU) admission, and in-hospital …
(combination of severity indicators), intensive care unit (ICU) admission, and in-hospital …
[HTML][HTML] Severity of COVID-19 among hospitalized patients: omicron remains a severe threat for immunocompromised hosts
L Nevejan, S Ombelet, L Laenen, E Keyaerts… - Viruses, 2022 - mdpi.com
The Omicron variant of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
emerged in the general population in the context of a relatively high immunity gained through …
emerged in the general population in the context of a relatively high immunity gained through …
[HTML][HTML] Serial measurement of circulating calprotectin as a prognostic biomarker in COVID-19 patients in intensive care setting
L Nevejan, T Strypens, M Van Nieuwenhove… - Clinical Chemistry and …, 2023 - degruyter.com
Objectives Circulating calprotectin (cCLP) has been shown to be a promising prognostic
marker for COVID-19 severity. We aimed to investigate the prognostic value of serial …
marker for COVID-19 severity. We aimed to investigate the prognostic value of serial …
[HTML][HTML] Early SARS-CoV-2 reinfections within 60 days and implications for retesting policies
L Nevejan, L Cuypers, L Laenen… - Emerging Infectious …, 2022 - ncbi.nlm.nih.gov
Illustrated by a clinical case supplemented by epidemiologic data, early reinfections with
SARS-CoV-2 Omicron BA. 1 after infection with Delta variant, and reinfection with Omicron BA. …
SARS-CoV-2 Omicron BA. 1 after infection with Delta variant, and reinfection with Omicron BA. …
[HTML][HTML] Circulating calprotectin as biomarker in neutrophil-related inflammation: pre-analytical recommendations and reference values according to sample type
M Mylemans, L Nevejan, S Van Den Bremt… - Clinica Chimica …, 2021 - Elsevier
Background Calprotectin (CLP) is a promising biomarker for the evaluation of neutrophil-related
inflammation. Our aim was to establish reference values for circulating CLP in different …
inflammation. Our aim was to establish reference values for circulating CLP in different …
Malignant progression of donor-engrafted clonal hematopoiesis in sibling recipients after stem cell transplantation
L Nevejan, F Nollet, H Devos, M Vynck… - Blood …, 2020 - ashpublications.org
The recent study of Boettcher et al1 describes 5 cases of donor-engrafted clonal hematopoiesis
(CH), one of which progressed into myelodysplastic syndrome (MDS) in both donor and …
(CH), one of which progressed into myelodysplastic syndrome (MDS) in both donor and …
Chronic myeloid leukemia (CML) in children and adolescents—Clinicopathological findings
L Nevejan, V Labarque… - European Journal of …, 2024 - Wiley Online Library
Background Barely two per million Belgian children/adolescents are diagnosed with chronic
myeloid leukemia (CML) annually. In this retrospective study, we aimed to investigate the …
myeloid leukemia (CML) annually. In this retrospective study, we aimed to investigate the …
Early SARS-CoV-2 reinfections within 60 days highlight the need to consider antigenic variations together with duration of immunity in defining retesting policies
L Nevejan, L Cuypers, L Laenen, L Van Loo… - medRxiv, 2022 - medrxiv.org
The emergence of the SARS-CoV-2 Omicron variant, characterized by a significant antigenic
diversity compared to the previous Delta variant, had led to a decrease in antibody efficacy …
diversity compared to the previous Delta variant, had led to a decrease in antibody efficacy …
[HTML][HTML] Diagnostic and analytical performance evaluation of ten commercial assays for detecting SARS-CoV-2 humoral immune response
M Mylemans, E Van Honacker, L Nevejan… - Journal of …, 2021 - Elsevier
Objective Analytical validation of newly released SARS-CoV-2 antibody assays in the clinical
laboratory is crucial to ensure sufficient performance in respect to its intended use. We …
laboratory is crucial to ensure sufficient performance in respect to its intended use. We …
Efficacy of ruxolitinib in B‐lymphoblastic leukaemia with the PCM1–JAK2 fusion gene.
Y Wouters, L Nevejan, A Louwagie… - British journal of …, 2021 - search.ebscohost.com
Keywords: PCM1-JAK2; ruxolitinib; B-ALL; t (8; 9); PCM1 EN PCM1-JAK2 ruxolitinib B-ALL t
(8; 9) PCM1 e112 e115 4 02/17/21 20210215 NES 210215 The I PCM1-JAK2 i fusion gene …
(8; 9) PCM1 e112 e115 4 02/17/21 20210215 NES 210215 The I PCM1-JAK2 i fusion gene …
